Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

Repeated Implantation Failure Clinical Trial

Official title:

Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01493440
• Other study ID #: IVFAS1103
• Status: Completed
• Phase: N/A
• First received: December 14, 2011
• Last updated: December 16, 2011
• Start date: March 2011
• Est. completion date: September 2011

Study information

• Verified date: December 2011
• Source: An Sinh Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Vietnam: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).

Description:

Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood supply. These effects are of potential benefit for implantation support during IVF-ET cycles.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 71
• Est. completion date: September 2011
• Est. primary completion date: August 2011
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• had repeated implantation failure

• have at least 1 good quality embryo for transfer

Exclusion Criteria:

• uterine abnormalities that could compromise the implantation process (e.g. fibroids, endometrial polyp, bicornuate uterus, adhesion of uterine cavity)

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Repeated Implantation Failure

Intervention

Drug:
• atosiban
Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.

Locations

Country	Name	City	State
Vietnam	IVFAS, An Sinh Hospital	Ho Chi Minh City	Ho Chi Minh

Sponsors (2)

Lead Sponsor	Collaborator
An Sinh Hospital	Vietnam National University

Country where clinical trial is conducted

Vietnam, 

References & Publications (1)

Moraloglu O, Tonguc E, Var T, Zeyrek T, Batioglu S. Treatment with oxytocin antagonists before embryo transfer may increase implantation rates after IVF. Reprod Biomed Online. 2010 Sep;21(3):338-43. doi: 10.1016/j.rbmo.2010.04.009. Epub 2010 Apr 18. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical pregnancy		5 weeks after intervention	No